Product
APX005M
11 clinical trials
27 indications
Indication
CancerIndication
NSCLCIndication
MelanomaIndication
Bladder CancerIndication
MSI-HIndication
Head and Neck CancerIndication
Non Small Cell Lung Cancer MetastaticIndication
Metastatic MelanomaIndication
Lung NeoplasmIndication
Soft Tissue SarcomaIndication
Pancreatic CancerIndication
Pancreatic AdenocarcinomaIndication
Squamous Cell Carcinoma of PancreasIndication
Adenosquamous Carcinoma of the PancreasIndication
Rectal AdenocarcinomaIndication
Ovarian CancerIndication
Glioblastoma MultiformeIndication
AstrocytomaIndication
central nervous system primary tumorIndication
NOSIndication
EpendymomaIndication
Diffuse Intrinsic Pontine GliomasIndication
MedulloblastomaIndication
Lung CancerIndication
Renal Cell CarcinomaIndication
Esophageal cancerIndication
Gastric Esophageal CancerClinical trial
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid TumorsStatus: Completed, Estimated PCD: 2018-06-13
Clinical trial
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic MelanomaStatus: Completed, Estimated PCD: 2020-11-16
Clinical trial
A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced SarcomasStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase Ib/II Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and APX005M in Patients With Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 AgonistStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
An Early Phase Randomized Trial of APX005M in BRCAwt Patients With Recurrent Ovarian CancerStatus: Withdrawn, Estimated PCD: 2023-09-07
Clinical trial
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem GliomaStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 TherapyStatus: Active (not recruiting), Estimated PCD: 2022-01-05
Clinical trial
A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction CancersStatus: Completed, Estimated PCD: 2022-11-10
Clinical trial
A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01